Products for Research Use Only

Rofecoxib-d5

CAT: 0804-HY-17372SSize: 500 µgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-17372SSize:500 µg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Rofecoxib-d5 is the deuterium labeled Rofecoxib. Rofecoxib is a potent, specific and orally active COX-2 inhibitor, with IC50s of 26 and 18 nM for human COX-2 in human osteosarcoma cells and Chinese hamster ovary cells, with a 1000-fold selectivity for COX-2 over human COX-1 (IC50 > 50 μM in U937 cells and > 15 μM in Chinese hamster ovary cells) [1][2].
CAS Number
544684-93-7
UNSPSC
12352005
Hazard Statement
H302+H312+H332-H315-H319
Target
COX; Isotope-Labeled Compounds
Type
Isotope-Labeled Compounds
Related Pathways
Immunology/Inflammation; Others
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Cancer
Solubility
10 mM in DMSO
Smiles
O=C1C(C2=C([2H])C([2H])=C([2H])C([2H])=C2[2H])=C(C3=CC=C(C=C3)S(C)(=O)=O)CO1
Molecular Formula
C17H9D5O4S
Molecular Weight
319.39
Precautions
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P501
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Rofecoxib, et al. Rofecoxib [Vioxx, MK-0966; 4- (4'-methylsulfonylphenyl) -3-phenyl-2- (5H) -furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther. 1999 Aug;290 (2) :551-60.|[3]Liu NN, et al. Rofecoxib inhibits retinal neovascularization via down regulation of cyclooxygenase-2 and vascular endothelial growth factor expression. Clin Exp Ophthalmol. 2015 Jul;43 (5) :458-65.|[4]Stoppoloni D, et al. Synergistic effect of gefitinib and rofecoxib in mesothelioma cells. Mol Cancer. 2010 Feb 2;9:27.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported

Alternative Products